Lakefront Biotherapeutics
LKFT
Lakefront Biotherapeutics (LKFT) earnings history
Most recent quarter
- Fiscal period
- Q1 2026
- Period end
- Mar 31, 2026
- EPS actual
- $0.25
- EPS estimate
- −$0.94
- EPS surprise
- +126.32%
- Revenue surprise
- −77.47%
- Revenue
- $7.6M
- Revenue estimate
- $33.9M
- Reported
- May 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | −$0.94 | $0.25 | +126.32% | $7.6M | SEC |
| Q4 2025 | Feb 23, 2026 | −$0.13 | $13.90 | +11088.22% | $1.0B | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.48 | −$3.54 | −641.44% | $82.1M | SEC |
| Q2 2025 | Jul 24, 2025 | −$0.23 | −$1.85 | −711.65% | $76.8M | SEC |
| Q1 2025 | Apr 23, 2025 | −$0.14 | −$2.67 | −1783.58% | $85.3M | SEC |
| Q4 2024 | Feb 12, 2025 | −$0.55 | $0.30 | +155.11% | $79.3M | SEC |
| Q3 2024 | Oct 31, 2024 | −$0.17 | −$0.80 | −374.54% | $65.0M | SEC |
| Q2 2024 | Invalid Date | −$0.07 | $0.08 | +205.53% | $86.2M | — |
| Q1 2024 | May 3, 2024 | −$0.08 | $0.39 | +561.43% | $67.2M | SEC |
| Q3 2023 | Nov 3, 2023 | −$1.13 | $0.42 | +137.19% | $128.9M | SEC |
| Q2 2023 | Aug 4, 2023 | −$0.82 | $0.09 | +110.79% | $165.3M | SEC |
| Q1 2023 | May 5, 2023 | −$0.96 | $0.39 | +140.15% | $196.9M | SEC |
| Q4 2022 | Feb 24, 2023 | −$0.65 | −$3.32 | −412.36% | $100.5M | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.81 | $0.33 | +140.51% | $135.6M | — |
| Q2 2022 | Aug 8, 2022 | −$0.68 | −$0.29 | +56.70% | $140.1M | — |
| Q1 2022 | May 6, 2022 | −$0.68 | −$0.21 | +68.70% | $144.2M | — |
| Q4 2021 | Mar 24, 2022 | −$1.04 | $0.28 | +126.93% | $206.9M | — |
| Q3 2021 | Nov 8, 2021 | −$1.70 | −$1.14 | +32.77% | $88.9M | — |
| Q2 2021 | Aug 5, 2021 | −$1.44 | −$1.15 | +19.89% | $179.9M | — |
| Q1 2021 | May 11, 2021 | −$1.12 | −$0.23 | +79.35% | $150.8M | — |
Quarterly revenue
Frequently asked questions
When did Lakefront Biotherapeutics (LKFT) last report earnings?
Lakefront Biotherapeutics last reported on May 6, 2026, covering fiscal Q1 2026.
Did LKFT beat earnings estimates?
Yes. Lakefront Biotherapeutics reported EPS of $0.25 for Q1 2026 against a −$0.94 estimate — a 126.32% beat.
How much revenue did LKFT report last quarter?
Lakefront Biotherapeutics reported $7.6M in revenue for Q1 2026, against a consensus estimate of $33.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.